drugset / Trial / NCT05697016
Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-Blind, placebo-controlled trial aimed to investigate the safety and efficacy of sivelestat on treating adult patients with COVID-19-related acute respiratory distress syndrome (ARDS)
Timeline
- Start
- 2023-01-31
- Primary completion
- 2024-01-03
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sivelestat | Small molecule | 0.2 mg/kg | Intravenous |